Anti-Müllerian hormone and HOMA-IR in different phenotypes of polycystic ovary syndrome on insulin resistance

Abstract

Aims: To examine the link between serum anti-mullerian hormone (AMH) levels and homeostatic model assessment of insulin resistance (HOMA-IR) in different phenotypes of polycystic ovary syndrome (PCOS).
 Methods: This retrospective study included 120 patients aged 18-30 who visited our polyclinics between June 2021 and December 2022. Patients were divided into four groups based on the Rotterdam criteria for PCOS phenotypes. A control group of 24 individuals was also included. Clinical data, hormonal profiles, and metabolic parameters were obtained from medical records.
 Results: There were significant differences in AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), and high-density lipoprotein (HDL) levels among the PCOS phenotypes and control group. AMH levels were highest in phenotype 1 (oligo/anovulation + hyperandrogenism + polycystic ovaries) and lowest in the control group. FSH were highest in phenotype 4 (oligo/anovulation + polycystic ovaries) and lowest in the control group. LH were highest in phenotype 2 (oligo/anovulation + hyperandrogenism). HOMA-IR was highest in phenotype 1. However, there were no significant differences in AMH or HOMA-IR levels among the PCOS phenotypes.
 Conclusion: Our study found hormone level differences among PCOS phenotypes but no significant differences in AMH or HOMA-IR. This suggests AMH may not distinguish between phenotypes and insulin resistance may not differ significantly among phenotypes.